Grifols, S.A. (NASDAQ:GRFS) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund reduced its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 20.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,629,272 shares of the biotechnology company’s stock after selling 429,014 shares during the period. New York State Common Retirement Fund’s holdings in Grifols were worth $12,122,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in Grifols during the fourth quarter worth about $28,000. GAMMA Investing LLC increased its position in Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,527 shares during the period. Signaturefd LLC boosted its holdings in shares of Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,153 shares during the period. Blue Trust Inc. grew its position in Grifols by 254.0% in the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 4,970 shares during the last quarter. Finally, HighTower Advisors LLC raised its holdings in shares of Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 1,546 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on GRFS shares. Morgan Stanley began coverage on Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating for the company. Berenberg Bank upgraded Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Trading Down 0.3 %

Grifols stock opened at $7.43 on Tuesday. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $9.96. The firm’s 50 day moving average price is $7.37 and its two-hundred day moving average price is $8.09. The firm has a market cap of $5.11 billion, a price-to-earnings ratio of 6.35 and a beta of 0.40. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.